Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), ...
Zudem haben viele Apotheker Aktien der Stada Arzneimittel AG gehalten, da dies eine Voraussetzung dafür war, um bestimmte ...
Stada Arzneimittel AG’s private equity owners have selected bookrunners for a potential initial public offering of the ...
The new 100,000 sqm facility required an investment of around $75m. It has an annual production capacity of 150 million packs ...
A growing number of German firms are gearing up to go public in the coming months despite worries over Europe’s largest ...
STADA opens new production site & supply-chain hub in Turda, Romania with an investment of US$ 75 million: Bad Vilbel, ...
About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...
Stada Arzneimittel AG’s private equity owners have expanded the lineup to help lead a potential initial public offering of the German generic drugmaker, according to people familiar with the matter.
Der Verkaufsprozess bei Stada zieht sich in die Länge. Laut einem Bericht der Nachrichtenagentur Bloomberg wird ein Börsengang wahrscheinlicher. Verhandelt wird laut Bericht mit dem ...
An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – ...
Du übernimmst die Verantwortung für die Gewinn- und Verlustrechnung (P&L) der STADA AG, einschließlich Corporate FP&A, Konsolidierung sowie dem Verständnis und der Herausforderung aller Corporate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback